about
Relative adrenal insufficiency in mice deficient in 5α-reductase 1Dutasteride for the treatment of benign prostatic hyperplasia.5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system.Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.Targeting 5α-reductase for prostate cancer prevention and treatmentAdvances in the design and discovery of drugs for the treatment of prostatic hyperplasia.Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation.The effect of pulsed electromagnetic fields and dehydroepiandrosterone on viability and osteo-induction of human mesenchymal stem cells.Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures.Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.Patients with Persistently Elevated PSA and Negative Results of TRUS-Biopsy: Does 6-Month Treatment with Dutasteride can Indicate Candidates for Re-Biopsy. What is the Best of Saturation Schemes: Transrectal or Transperineal Approach?The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
P2860
Q33922259-E186DFD5-A571-4662-8BD9-71ABB6500D94Q34349726-23545FFA-D19E-4D47-85E3-6491061E48A5Q34887797-06CBF132-A215-40F6-B6A3-17880C642648Q35723500-6A147468-D1E3-4564-98C7-A8716D5EB73EQ36434305-36D914A2-29A8-49A7-8A60-4F7475348577Q37883012-808959AC-5C25-4D6A-B191-D885F964F294Q38105608-9932A04D-7F84-4FA9-AE40-8ECCA5789F04Q38995986-79375231-F923-4EED-ADC9-548E26C98195Q39265488-B57C86FF-64AC-4D67-B086-4F4D10A5EC02Q41310160-CCACA447-AC9E-47A1-995A-B874BC2F2075Q48553280-AB512DCC-89F6-4325-90CC-72E69CFFADA6Q50505330-4A2F0742-D190-4422-B804-84157E0C930DQ53584676-20AA78EF-D871-46F4-80DF-82795D706E7EQ55019942-2DABB555-5E71-44E4-A8BA-F2A538B54414
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Dutasteride.
@ast
Dutasteride.
@en
type
label
Dutasteride.
@ast
Dutasteride.
@en
prefLabel
Dutasteride.
@ast
Dutasteride.
@en
P1433
P1476
Dutasteride.
@en
P2093
Hannah C Evans
Karen L Goa
P304
905-16; discussion 917-8
P356
10.2165/00002512-200320120-00005
P577
2003-01-01T00:00:00Z
P6179
1034780460